{"id":17237,"date":"2025-08-20T21:33:44","date_gmt":"2025-08-20T16:03:44","guid":{"rendered":"http:\/\/43.205.138.160\/?post_type=article&p=17237"},"modified":"2025-08-20T21:33:44","modified_gmt":"2025-08-20T16:03:44","slug":"daily-analysis-on-auropharma","status":"publish","type":"article","link":"https:\/\/signalz.pro\/article\/daily-analysis-on-auropharma\/","title":{"rendered":"Daily Analysis on AUROPHARMA"},"content":{"rendered":"

Aurobindo Pharma (AUROPHARMA) \u2013 Full Analysis<\/u><\/strong><\/p>\n

Technical View
\n<\/strong>As seen in the daily chart, the stock showed high volatility<\/strong> today.
\nOpened at \u20b91070<\/strong>, made a high of \u20b91071<\/strong>, low of \u20b91040.20<\/strong>, and closed at \u20b91046.40<\/strong>.
\nThe stock is facing resistance near the 14-day EMA<\/strong> and failed to close above \u20b91080<\/strong>, indicating no short-term buy signal yet.
\nOn the weekly chart<\/strong>, the stock is holding support near the 200-day EMA<\/strong> and the crucial \u20b9995 zone<\/strong>.
\nIn the long term<\/strong>, any dip towards the \u20b91000\u20131020 zone could provide a buy-on-dips opportunity<\/strong>.
\nUpside potential: Over the next 6\u20138 months<\/strong>, the stock may retest the \u20b91250\u20131300 levels<\/strong> if support sustains<\/p>\n

Fundamental View<\/strong>
\nBusiness Model<\/strong>: AUROPHARMA is among India\u2019s top pharmaceutical companies with a strong presence in generic drugs, formulations, and APIs<\/strong> across regulated markets (US, EU).<\/p>\n

Financials<\/strong>:
\nRevenue growth supported by US formulations and API exports.
\nMargins under pressure due to pricing challenges in US generics<\/strong> and higher R&D expenses<\/strong>.
\nDebt levels reducing gradually, improving balance sheet strength.<\/p>\n

Valuation<\/strong>: Currently trading below its historical P\/E average, making it attractive for long-term investors.<\/p>\n

Micro Factors (Company-specific)
\n<\/strong>Strong USFDA-approved manufacturing base.
\n<\/strong>Expansion in injectables and biosimilars<\/strong>.
\n<\/strong>Cost optimization initiatives in place.
\n<\/strong>Near-term margin pressure due to raw material cost and pricing erosion.<\/p>\n

Macro Factors (Industry & Economy)
\n<\/strong>Pharma sector benefiting from global demand for affordable generics<\/strong>.
\n<\/strong>INR depreciation supports exporters like AUROPHARMA.
\n<\/strong>Regulatory risk (USFDA audits, compliance) remains a key overhang.
\n<\/strong>Healthcare spending in emerging markets is increasing, aiding growth.<\/p>\n

Upcoming Events & Impact
\nQ2 FY26 Results (November 2025)<\/strong> \u2192 Expected to reflect better US business traction. Positive results could trigger momentum.
\nProduct Launches in US\/Europe<\/strong> \u2192 Likely to enhance revenue visibility.
\nUSFDA Inspection Outcomes<\/strong> \u2192 Any adverse report may negatively impact the stock in short term.
\nGlobal Drug Pricing Trends<\/strong> \u2192 A major determinant of profitability.<\/p>\n

Disclaimer
\n<\/strong>This analysis is for educational & informational purposes only<\/strong> and should not be considered as investment advice.<\/p>\n

Disclosure
\n<\/strong>We, at Investogainer Research<\/strong>, SEBI Registered Research Analyst (INH000012856) & BSE Listed (Code: 5845), do not hold any personal\/family interest or position in Aurobindo Pharma at the time of publishing this analysis.<\/p>\n

For More Info:
\nVisit Us- www.investogainerresearch.com<\/a>
\nCall Us- 9009099805, 9098804206
\nEmail Us- info@investogainerresearch.com<\/a> <\/strong>Daily Analysis on AUROPHARMA on 20082025<\/a><\/p>\n","protected":false},"template":"","article-category":[35],"article-tags":[400,130,163,121,235,92,129,162,168,127],"class_list":["post-17237","article","type-article","status-publish","hentry","article-category-learn","article-tags-technicalanalysis","article-tags-expert-analysis","article-tags-financialeducation","article-tags-investment-opportunities","article-tags-nifty50","article-tags-sebi-registered-advisors","article-tags-stock-market-tips","article-tags-stockmarket","article-tags-stockmarkettips","article-tags-successful-investing"],"acf":[],"_links":{"self":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article\/17237","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article"}],"about":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/types\/article"}],"wp:attachment":[{"href":"https:\/\/signalz.pro\/api\/wp\/v2\/media?parent=17237"}],"wp:term":[{"taxonomy":"article-category","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-category?post=17237"},{"taxonomy":"article-tags","embeddable":true,"href":"https:\/\/signalz.pro\/api\/wp\/v2\/article-tags?post=17237"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}